​

BridgeBio Pharma (BBIO) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

BBIO Stock Forecast

BridgeBio Pharma (BBIO) stock forecast, based on 19 Wall Street analysts, predicts a 12-month average price target of $45.00, with a high of $45.00 and a low of $45.00. This represents a 32.86% increase from the last price of $33.87.

$20 $25 $30 $35 $40 $45 High: $45 Avg: $45 Low: $45 Last Closed Price: $33.87

BBIO Stock Rating

BridgeBio Pharma stock's rating consensus is Buy, based on 19 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 18 Buy (94.74%), 1 Hold (5.26%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 19 0 1 18 Strong Sell Sell Hold Buy Strong Buy

BBIO Price Target Upside V Benchmarks

TypeNameUpside
StockBridgeBio Pharma32.86%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts--11
Avg Price Target--$47.36
Last Closing Price$33.87$33.87$33.87
Upside/Downside--39.83%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 256103--19
Mar, 25693--18
Feb, 25593--17
Jan, 25693--18
Dec, 24792--18
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 24, 2024David LebowitzCitigroup$45.00$24.1786.18%32.86%
Oct 17, 2024Mani ForooharLeerink Partners$46.00$26.3474.64%35.81%
Sep 11, 2024Biren AminPiper Sandler$46.00$28.7859.83%35.81%
Sep 03, 2024Salim SyedMizuho Securities$53.00$29.9277.14%56.48%
Jun 24, 2024Danielle BrillRaymond James$46.00$22.65103.09%35.81%
Jun 05, 2024Kostas BiliourisBMO Capital$37.00$26.9337.39%9.24%
Jun 05, 2024Tiago FauthWells Fargo$58.00$27.13113.79%71.24%
May 30, 2024Paul ChoiGoldman Sachs$50.00$27.6181.09%47.62%
May 28, 2024Eliana MerleUBS$47.00$27.9468.22%38.77%
May 20, 2024Raghuram SelvarajuH.C. Wainwright$43.00$30.0942.90%26.96%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 24, 2024CitigroupBuyBuyhold
Oct 02, 2024OppenheimerPerforminitialise
Sep 24, 2024BMO CapitalMarket PerformMarket Performhold
Sep 11, 2024Piper SandlerOverweightOverweighthold
Sep 04, 2024Piper SandlerOverweightinitialise
Sep 03, 2024H.C. WainwrightBuyBuyhold
Jun 24, 2024Raymond JamesOutperformOutperformhold
Jun 24, 2024Evercore ISIOutperformOutperformhold
Jun 10, 2024Cowen & Co.BuyBuyhold
Jun 05, 2024BMO CapitalOutperformOutperformhold

Financial Forecast

EPS Forecast

$-10 $-7 $-4 $-1 $2 $5 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-4.10$-4.43$-3.35$-3.95$-2.88----
Avg Forecast$-3.52$-3.70$-3.13$-3.76$-2.52$-3.55$-2.51$-0.57$1.91
High Forecast$-1.46$-1.53$-1.18$-3.60$-2.32$-2.63$-0.86$0.68$4.02
Low Forecast$-8.94$-9.39$-7.28$-3.97$-2.70$-4.27$-3.28$-0.95$0.30
Surprise %16.48%19.73%7.03%5.05%14.29%----

Revenue Forecast

$0 $700M $1B $2B $3B $4B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$8.25M$69.72M$77.65M$9.30M$221.90M----
Avg Forecast$22.52M$78.26M$82.75M$12.29M$219.05M$176.98M$437.33M$967.67M$1.67B
High Forecast$49.15M$170.79M$167.23M$16.09M$230.15M$313.43M$442.24M$1.01B$3.08B
Low Forecast$12.38M$43.03M$43.07M$7.40M$214.98M$64.02M$432.43M$928.41M$588.98M
Surprise %-63.37%-10.91%-6.16%-24.31%1.30%----

Net Income Forecast

$-1B $-600M $-200M $200M $600M $1B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-483.93M$-639.30M$-493.96M$-643.20M$-535.76M----
Avg Forecast$-362.63M$-450.77M$-570.76M$-643.20M$-438.86M$-561.83M$-336.28M$-21.66M$311.59M
High Forecast$-290.11M$-360.62M$-456.61M$-514.56M$-376.93M$-428.14M$-139.25M$110.71M$654.37M
Low Forecast$-435.16M$-540.92M$-684.91M$-771.84M$-439.49M$-695.53M$-533.31M$-154.03M$49.48M
Surprise %33.45%41.82%-13.45%-22.08%----

BBIO Forecast FAQ

Is BridgeBio Pharma stock a buy?

BridgeBio Pharma stock has a consensus rating of Buy, based on 19 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 18 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that BridgeBio Pharma is a favorable investment for most analysts.

What is BridgeBio Pharma's price target?

BridgeBio Pharma's price target, set by 19 Wall Street analysts, averages $45 over the next 12 months. The price target range spans from $45 at the low end to $45 at the high end, suggesting a potential 32.86% change from the previous closing price of $33.87.

How does BridgeBio Pharma stock forecast compare to its benchmarks?

BridgeBio Pharma's stock forecast shows a 32.86% upside, underperforming the average forecast for the healthcare stocks sector (35.25%) and underperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for BridgeBio Pharma over the past three months?

  • April 2025: 31.58% Strong Buy, 52.63% Buy, 15.79% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 33.33% Strong Buy, 50.00% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 29.41% Strong Buy, 52.94% Buy, 17.65% Hold, 0% Sell, 0% Strong Sell.

What is BridgeBio Pharma’s EPS forecast?

BridgeBio Pharma's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.55, marking a 23.26% increase from the reported $-2.88 in 2024. Estimates for the following years are $-2.51 in 2026, $-0.57 in 2027, and $1.91 in 2028.

What is BridgeBio Pharma’s revenue forecast?

BridgeBio Pharma's average annual revenue forecast for its fiscal year ending in December 2025 is $176.98M, reflecting a -20.24% decrease from the reported $221.9M in 2024. The forecast for 2026 is $437.33M, followed by $967.67M for 2027, and $1.67B for 2028.

What is BridgeBio Pharma’s net income forecast?

BridgeBio Pharma's net income forecast for the fiscal year ending in December 2025 stands at $-562M, representing an 4.87% increase from the reported $-536M in 2024. Projections indicate $-336M in 2026, $-21.661M in 2027, and $311.59M in 2028.